Canada - anglais - Health Canada

pharmascience inc - dihydroergotamine mesylate - liquid - 4mg - dihydroergotamine mesylate 4mg - sympatholytic (adrenergic blocking) agents

Canada - anglais - Health Canada

pharmascience inc - dihydroergotamine mesylate - liquid - 1mg - dihydroergotamine mesylate 1mg - sympatholytic (adrenergic blocking) agents

Canada - anglais - Health Canada

sandoz canada incorporated - dihydroergotamine mesylate - liquid - 1mg - dihydroergotamine mesylate 1mg - sympatholytic (adrenergic blocking) agents

États-Unis - anglais - NLM (National Library of Medicine)

gland pharma limited - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate injection is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore contraindicated (see warnings: cyp3a4 inhibitors).   dihydroergotamine mesylate injection should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal’s variant angi

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dihydroergotamine mesilate 2 mg/ml - oral solution - 2 mg/ml - active: dihydroergotamine mesilate 2 mg/ml

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dihydroergotamine mesilate 1 mg/ml - solution for injection - 1 mg/ml - active: dihydroergotamine mesilate 1 mg/ml

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dihydroergotamine mesilate 1mg - tablet - 1 mg - active: dihydroergotamine mesilate 1mg

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - dihydroergotamine mesilate 2.5mg - tablet - 2.5 mg - active: dihydroergotamine mesilate 2.5mg

Australie - anglais - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - saquinavir mesilate, quantity: 571.5 mg (equivalent: saquinavir, qty 500 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; triacetin; croscarmellose sodium; titanium dioxide; hypromellose; purified talc; iron oxide red; lactose monohydrate; iron oxide yellow; magnesium stearate - invirase (saquinavir) is indicated for the treatment of hiv/aids in adults and children 12 years of age or older. clinical studies indicate that saquinavir should only be used in combination with ritonavir and other anti-retroviral therapies (see clinical trials). this indication is based on changes in surrogate markers. at present there are no results from controlled clinical trials evaluating the effect of regimens containing saquinavir on hiv disease progression or survival (see clinical trials).

États-Unis - anglais - NLM (National Library of Medicine)

hikma farmaceutica - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) -